Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(l-piperidino)-l-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks

Cancer Research

Volumn 54, Issue 2, 1994, Pages 427-436

  Rock, Michael K ^b   Grochow, Louise B ^a   Ettinger, David S ^a   Sartorius, Susan E ^a   Lubejko, Barbara G ^a   Chen, Tian Ling ^a   Donehower, Ross C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b G H Besselaar Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DIPHENHYDRAMINE; IRINOTECAN; ONDANSETRON; TOPOTECAN;

ABDOMINAL CRAMP; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIAPHORESIS; DIARRHEA; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SOLID TUMOR; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; HUMAN; INFUSIONS, INTRAVENOUS; MIDDLE AGE; MUSCLE CRAMP; NEOPLASMS; NEUTROPENIA; SUPPORT, NON-U.S. GOV'T; THROMBOCYTOPENIA; VOMITING;

EID: 0028158012     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Slichenmyer, W.J., Rowinsky, E.K., Donehower, R.C., and Kaufmann, S.H. The current status of camptothecin analogues as anticancer agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
2. Schaeppi, U., Fleischman, R.W., and Cooney, D.A. Toxicity of camptothecin (NSC-10080). Cancer Chemother. Rep., 5: 25-36, 1974.
3. Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T., and Block, J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54: 461-470, 1970.
4. Muggia, F.M., Creaven, P.J., Hansen, H.H., and Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515-521, 1972.
5. Gottlieb, J.A., and Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 56: 103-105, 1972.
6. Moertel, C.G., Schutt, A.J., Reitmeier, R.J., and Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
7. Creaven, P.J., Allen, L.M., and Muggia, F.M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother. Rep., 56: 573-578, 1972.
8. Wani, M.C., Ronman, P.E., Lindley, J.T., and Wall, M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem., 23: 554-560, 1980.
9. Hertzberg, R.P., Caranafa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K., and Kingsbury, W.D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
10. Kingsbury, W.D., Boehm, J.C., Jakas, D.R., Holden, K.G., Hecht, S.M., Gallagher, G., Caranfa, J.J., McCabe, F.L., Faucette, L.F., Johnson, R.K., and Hertzberg, R. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
11. Staubus, A.E., Rutherford, M., Snuffer, P., and Feller, D. Kinetics of ring opening of camptothecin analogues and topotecan in plasma and whole blood. Proc. Am. Assoc. Cancer Res., 33: 531, 1992.
12. Miyasaka, T., Mutai, M., Sawada, S., Nokata, K., and Hagiwara, H. Synthesis of new camptothecin derivatives. Japanese Patent: Kokai, 56-158786, 1981.
13. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(l-piperidino)-l-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944-5947, 1987.
14. Furuta, T., Yokokura, T., and Mutai, M. Antitumor activity of CPT-11 against rat Walker 256 carcinoma. Jpn. J. Cancer Chemother., 15: 2757-2760, 1988.
15. Bissery MC, Matthieu-Boue, and Lavelle F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Can. Res., 32: 402, 1991.
16. Bissery, M.C., Mathieu-Bouse, A., and Lavelle F. Experimental antitumor evidence of CPT-11 in vitro and in vivo. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs In Cancer Therapy 82, 1992.
17. Matsuzaki, T., Yokokura, T., Mutai, M., and Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol., 21: 308-312, 1988.
18. Tsuruo, T., Matsuzaki, T., Matsushita, M., Saito, H., and Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 21: 71-74, 1988.
19. Kawato, Y., Furuta, T., Aonuma, M., Yokokura, T., and Matsumoto, K. Antitumor activity of a camptothecin derivative, CPT-11, against tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192-198, 1991.
20. Wang, Y., Inoue, K., Shibata, H., Itoh, Y., Chen, S.C., and Ogawa, M. Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Jpn. J. Cancer Chemother., 14: 1264-1270, 1987.
21. Rowinsky, E., Grochow, L., Hendricks, C., Sartorius, S., Ettinger, D., McGuire, W., Forastiere, A., Hurowitz, L., Easter, V., and Donehower, R. Phase I and pharmacologic study of topotecan (SK&F 104864): a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
22. Kaneda, N., Nagata, H., Furata, T., and Yokokura, T Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
23. Kawato, Y., Aonuma, M., Hirota, Y., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 57: 4187-4191, 1991.
24. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takiuji, N., Kudoh, S., Niita, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168, 1991.
25. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
26. Masuda, N., Fukuoka, R., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Negoro, S., Nishioka, M., Nakagawa, K., and Takada, M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol., 10: 1225-1229, 1992.
27. Shimada, Y., Yoshino, M., Wakui, A., Nakao, I., Futatsuki, K., Sakata, Y., Kambe, M., Taguchi, T., Ogawa, N., and the CPT-11 Gastrointestinal Study Group. Phase II study of CPT-11, new camptothecin derivative, in the patients with metastatic colorectal cancer. J. Clin. Oncol., 11: 909-913, 1993.
28. Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Shozo, Y., and Ota, K. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
29. Takeuchi, S., Takamizawa, H., Takeda, Y., Okawa, T., Tamaya, T., Noda, K., Sugawa, T., Sekiba, K., Yakushiji, M., and Taguchi, T., and the CPT-11 Study Group on Gynecologic Malignancy. Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc. Am. Soc. Clin. Oncol., 10: 189, 1991.
30. Takeuchi, S., Noda, K., Yakushiji, M., and the CPT-11 Study Group on Gynecologic Malignancy. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc. Am. Soc. Clin. Oncol., 11: 224, 1992.
31. Taguchi, T., Wakui, A., and Hasegawa, K. Phase I clinical study of CPT-11. Jpn. J. Chemother., 17: 115-120, 1990.
32. CPT-11 investigator's brochure. Princeton, NJ: Theradex, November 1992.
33. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
34. Beijnen, J.H., Smith, B.R., Keijer, W.J., Van Gijn, R., ten Bokkel Huinink, W.W., Vlasveld, L.T., Rodenhuis, S., and Underberg, W.J.M. High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
35. Chiou, W.L. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biophys., 6: 339-346, 1978.
36. Goldstein, A., Aronow, L., and Kalman, S. Principles of Drug Action. The Basics of Pharmacology, p. 83. New York: John Wiley and Sons., Inc., 1974.
37. Grochow, L.B., Rowinsky, E.K., Johnson, R., Ludeman, S., Kaufmann, S.H., McCabe, F.L., Smith, B.R., Hurowitz, L., DeLisa, A., Donehower, R.C., and Noe, D.A. Pharmacokinetics and pharmacodynamics of topotecan. Drug Metab. Dispos., 20: 706-713, 1992.
38. Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Tojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., Kanzawa, F., and Saijo, N. Phase I and pharmacokinetic study of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst., 12: 972-974, 1992.
39. Rothenberg, M.L., Kuhn, J.G., Burris, H.A., Nelson, J., Eckardt, J.R., Morales, M.T., Hilsenbeck, S.G., Weiss, G.R., Smith, L.S., Rodriguez, G.I., Rock, M.K., and Von Hoff, D.D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
40. Gandia, D., Abigerges, D., Armand, J.R., Chabot, G., Da Casta, L., De Forni, and Herait, P. CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol., 11: 196-197, 1993.
41. Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn., 14: 341-349, 1991.
42. Supko, J.G., and Malspeis, L. Pharmacokinetics of the 9-amino and 10, 11-methylenedioxy derivatives of campthothecin in mice. Cancer Res., 53: 3062-3069, 1993.
43. Chen, G., Portman, R., and Wickel, A. Pharmacology of l, l-dimethyl-4-phenylpiperazinium iodide, a ganglion-stimulating agent. J. Pharmacol. Exp. Ther., 103: 330-336, 1951.
44. Saski, Y., Morita, M., Miya, T., Shinkai, T., Eguchi, K., Tamura, T., Ohe, Y., and Saijo, N. Pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Proc. Am. Soc. Clin. Oncol., 11: 111, 1992.
45. Shimada, Y., Sasaki, Y., Sugano, K., Shirao, K., Kondo, H., Yokota, T., Saito, D., Tamura, T., and Ohe, Y., Shinkai, T., Eguchi, K., Saijo, N., and Shintani, S. Combination phase I study of CPT-11 (Irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 12: 196, 1993.